Indicator type	Main activity, secondary activity or tool required for...	Total
Companies carrying out R&D in Biotechnology	Total	1,376
Companies carrying out R&D in Biotechnology	Main	711
Companies carrying out R&D in Biotechnology	Secondary	270
Companies carrying out R&D in Biotechnology	Tool required	395
% Companies by type of biotechnology used: Genetic Code	Total	31.4
% Companies by type of biotechnology used: Genetic Code	Main	37.1
% Companies by type of biotechnology used: Genetic Code	Secondary	28.5
% Companies by type of biotechnology used: Genetic Code	Tool required	23.3
% Companies by type of biotechnology used: Functional Units	Total	43.7
% Companies by type of biotechnology used: Functional Units	Main	50.2
% Companies by type of biotechnology used: Functional Units	Secondary	38.9
% Companies by type of biotechnology used: Functional Units	Tool required	35.3
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Total	22.8
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Main	26.3
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Secondary	22.6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Tool required	16.8
% Companies by type of biotechnology used: Bioprocesses	Total	48.3
% Companies by type of biotechnology used: Bioprocesses	Main	38.7
% Companies by type of biotechnology used: Bioprocesses	Secondary	59.0
% Companies by type of biotechnology used: Bioprocesses	Tool required	58.2
% Companies by type of biotechnology used: Subcellular Organisms	Total	7.9
% Companies by type of biotechnology used: Subcellular Organisms	Main	10.6
% Companies by type of biotechnology used: Subcellular Organisms	Secondary	6.0
% Companies by type of biotechnology used: Subcellular Organisms	Tool required	4.2
% Companies by type of biotechnology used: Bioinformatics	Total	27.1
% Companies by type of biotechnology used: Bioinformatics	Main	34.0
% Companies by type of biotechnology used: Bioinformatics	Secondary	21.5
% Companies by type of biotechnology used: Bioinformatics	Tool required	18.7
% Companies by type of biotechnology used: Nanobiotechnology	Total	11.2
% Companies by type of biotechnology used: Nanobiotechnology	Main	14.5
% Companies by type of biotechnology used: Nanobiotechnology	Secondary	10.0
% Companies by type of biotechnology used: Nanobiotechnology	Tool required	6.2
% Companies by type of biotechnology used: Other	Total	17.6
% Companies by type of biotechnology used: Other	Main	19.2
% Companies by type of biotechnology used: Other	Secondary	17.3
% Companies by type of biotechnology used: Other	Tool required	15.0
% Companies by final application areas of biotechnology use: Human Health	Total	48.0
% Companies by final application areas of biotechnology use: Human Health	Main	64.5
% Companies by final application areas of biotechnology use: Human Health	Secondary	33.7
% Companies by final application areas of biotechnology use: Human Health	Tool required	28.1
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Total	16.9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Main	17.2
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Secondary	18.2
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Tool required	15.3
% Companies by final application areas of biotechnology use: Food Products	Total	29.4
% Companies by final application areas of biotechnology use: Food Products	Main	20.1
% Companies by final application areas of biotechnology use: Food Products	Secondary	34.5
% Companies by final application areas of biotechnology use: Food Products	Tool required	42.7
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Total	25.7
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Main	21.8
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Secondary	31.3
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Tool required	28.9
% Companies by final application areas of biotechnology use: Environment	Total	18.0
% Companies by final application areas of biotechnology use: Environment	Main	16.2
% Companies by final application areas of biotechnology use: Environment	Secondary	24.6
% Companies by final application areas of biotechnology use: Environment	Tool required	16.8
% Companies by final application areas of biotechnology use: Industry	Total	13.0
% Companies by final application areas of biotechnology use: Industry	Main	11.7
% Companies by final application areas of biotechnology use: Industry	Secondary	17.2
% Companies by final application areas of biotechnology use: Industry	Tool required	12.6
R&D personnel in Biotechnology (PP)	Total	17,257
R&D personnel in Biotechnology (PP)	Main	9,048
R&D personnel in Biotechnology (PP)	Secondary	4,028
R&D personnel in Biotechnology (PP)	Tool required	4,180
R&D personnel in Biotechnology (PP): Research personnel	Total	9,195
R&D personnel in Biotechnology (PP): Research personnel	Main	5,201
R&D personnel in Biotechnology (PP): Research personnel	Secondary	2,189
R&D personnel in Biotechnology (PP): Research personnel	Tool required	1,806
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Total	8,061
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Main	3,847
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Secondary	1,840
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Tool required	2,375
R&D personnel in Biotechnology (PP). Women	Total	9,980
R&D personnel in Biotechnology (PP). Women	Main	5,508
R&D personnel in Biotechnology (PP). Women	Secondary	2,308
R&D personnel in Biotechnology (PP). Women	Tool required	2,164
R&D personnel in Biotechnology (PP). Women: Research personnel	Total	5,222
R&D personnel in Biotechnology (PP). Women: Research personnel	Main	3,049
R&D personnel in Biotechnology (PP). Women: Research personnel	Secondary	1,239
R&D personnel in Biotechnology (PP). Women: Research personnel	Tool required	934
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Total	4,758
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Main	2,458
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Secondary	1,069
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Tool required	1,231
R&D personnel in Biotechnology (FTE)	Total	12,883.4
R&D personnel in Biotechnology (FTE)	Main	7,145.1
R&D personnel in Biotechnology (FTE)	Secondary	2,868.7
R&D personnel in Biotechnology (FTE)	Tool required	2,869.6
R&D personnel in Biotechnology (FTE): Research personnel	Total	7,103.2
R&D personnel in Biotechnology (FTE): Research personnel	Main	4,146.1
R&D personnel in Biotechnology (FTE): Research personnel	Secondary	1,664.6
R&D personnel in Biotechnology (FTE): Research personnel	Tool required	1,292.5
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Total	5,780.2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Main	2,999.0
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Secondary	1,204.1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Tool required	1,577.1
R&D personnel in Biotechnology (FTE). Women	Total	7,600.6
R&D personnel in Biotechnology (FTE). Women	Main	4,390.4
R&D personnel in Biotechnology (FTE). Women	Secondary	1,697.6
R&D personnel in Biotechnology (FTE). Women	Tool required	1,512.6
R&D personnel in Biotechnology (FTE). Women: Research personnel	Total	4,057.0
R&D personnel in Biotechnology (FTE). Women: Research personnel	Main	2,442.0
R&D personnel in Biotechnology (FTE). Women: Research personnel	Secondary	931.4
R&D personnel in Biotechnology (FTE). Women: Research personnel	Tool required	683.6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Total	3,543.7
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Main	1,948.5
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Secondary	766.2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Tool required	829.0
Expenditure on internal R&D in Biotechnology (thousands of euros)	Total	1,283,346
Expenditure on internal R&D in Biotechnology (thousands of euros)	Main	793,871
Expenditure on internal R&D in Biotechnology (thousands of euros)	Secondary	225,886
Expenditure on internal R&D in Biotechnology (thousands of euros)	Tool required	263,589
1) By type of expenditure: Current expenditure	Total	1,180,187
1) By type of expenditure: Current expenditure	Main	730,162
1) By type of expenditure: Current expenditure	Secondary	206,423
1) By type of expenditure: Current expenditure	Tool required	243,601
1.1) Labour expenditure of research personnel	Total	372,421
1.1) Labour expenditure of research personnel	Main	220,559
1.1) Labour expenditure of research personnel	Secondary	79,909
1.1) Labour expenditure of research personnel	Tool required	71,953
1.2) Labour expenditure of technical and auxiliary personnel	Total	229,734
1.2) Labour expenditure of technical and auxiliary personnel	Main	122,582
1.2) Labour expenditure of technical and auxiliary personnel	Secondary	46,028
1.2) Labour expenditure of technical and auxiliary personnel	Tool required	61,124
1.3) Other current expenditure	Total	578,032
1.3) Other current expenditure	Main	387,021
1.3) Other current expenditure	Secondary	80,486
1.3) Other current expenditure	Tool required	110,525
2) By type of expenditure: Capital expenditure	Total	103,159
2) By type of expenditure: Capital expenditure	Main	63,708
2) By type of expenditure: Capital expenditure	Secondary	19,463
2) By type of expenditure: Capital expenditure	Tool required	19,988
2.1) Land and buildings	Total	10,889
2.1) Land and buildings	Main	6,242
2.1) Land and buildings	Secondary	1,295
2.1) Land and buildings	Tool required	3,353
2.2) Equipment and tools	Total	59,204
2.2) Equipment and tools	Main	32,289
2.2) Equipment and tools	Secondary	13,987
2.2) Equipment and tools	Tool required	12,928
2.3) Acquisition of specific R&D software	Total	5,623
2.3) Acquisition of specific R&D software	Main	4,542
2.3) Acquisition of specific R&D software	Secondary	423
2.3) Acquisition of specific R&D software	Tool required	659
2.4) Other R&D-specific IP products	Total	27,442
2.4) Other R&D-specific IP products	Main	20,636
2.4) Other R&D-specific IP products	Secondary	3,758
2.4) Other R&D-specific IP products	Tool required	3,049
1.1) By origin of funds: Own funds	Total	887,527
1.1) By origin of funds: Own funds	Main	533,621
1.1) By origin of funds: Own funds	Secondary	160,796
1.1) By origin of funds: Own funds	Tool required	193,110
1.2) By origin of funds: Funds from the Business sector	Total	143,903
1.2) By origin of funds: Funds from the Business sector	Main	105,847
1.2) By origin of funds: Funds from the Business sector	Secondary	15,390
1.2) By origin of funds: Funds from the Business sector	Tool required	22,666
1.3) By origin of funds: Funds from the Public Administration sector	Total	126,546
1.3) By origin of funds: Funds from the Public Administration sector	Main	77,642
1.3) By origin of funds: Funds from the Public Administration sector	Secondary	25,443
1.3) By origin of funds: Funds from the Public Administration sector	Tool required	23,461
1.4) By origin of funds: Funds from the Higher Education sector	Total	94
1.4) By origin of funds: Funds from the Higher Education sector	Main	76
1.4) By origin of funds: Funds from the Higher Education sector	Secondary	0
1.4) By origin of funds: Funds from the Higher Education sector	Tool required	18
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Total	12,623
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Main	11,461
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Secondary	99
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Tool required	1,063
1.6) By origin of funds: Funds from the rest of the world	Total	112,652
1.6) By origin of funds: Funds from the rest of the world	Main	65,223
1.6) By origin of funds: Funds from the rest of the world	Secondary	24,158
1.6) By origin of funds: Funds from the rest of the world	Tool required	23,271
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Total	137,432
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Main	118,571
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Secondary	11,344
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Tool required	7,517
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Total	88,127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Main	73,357
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Secondary	8,570
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Tool required	6,200
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Total	49,305
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Main	45,214
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Secondary	2,774
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Tool required	1,318
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Total	43.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Main	52.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Secondary	38.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Tool required	32.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Total	16.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Main	15.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Secondary	21.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Tool required	14.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Total	23.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Main	25.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Secondary	21.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Tool required	22.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Total	14.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Main	14.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Secondary	15.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Tool required	13.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Total	18.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Main	20.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Secondary	17.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Tool required	14.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Total	19.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Main	22.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Secondary	17.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Tool required	15.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Total	19.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Main	18.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Secondary	21.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Tool required	18.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Total	49.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Main	54.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Secondary	46.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Tool required	43.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Total	59.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Main	66.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Secondary	57.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Tool required	48.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Total	22.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Main	22.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Secondary	20.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Tool required	23.7
% Companies with international revenues related to biotechnology activities	Total	23.6
% Companies with international revenues related to biotechnology activities	Main	30.8
% Companies with international revenues related to biotechnology activities	Secondary	19.3
% Companies with international revenues related to biotechnology activities	Tool required	13.3
% Companies representing international revenues related to biotechnology activities	Total	1.5
% Companies representing international revenues related to biotechnology activities	Main	14.7
% Companies representing international revenues related to biotechnology activities	Secondary	0.4
% Companies representing international revenues related to biotechnology activities	Tool required	0.8
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Total	57.6
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Main	64.5
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Secondary	38.7
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Tool required	47.7
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Total	42.4
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Main	35.5
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Secondary	61.3
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Tool required	52.3
% International revenues related to biotechnology activities by classification: International trade in goods and services	Total	82.3
% International revenues related to biotechnology activities by classification: International trade in goods and services	Main	77.1
% International revenues related to biotechnology activities by classification: International trade in goods and services	Secondary	90.6
% International revenues related to biotechnology activities by classification: International trade in goods and services	Tool required	95.7
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Total	14.1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Main	20.2
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Secondary	0.5
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Tool required	2.3
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Total	1.5
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Main	1.1
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Secondary	3.7
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Tool required	1.0
% International revenues related to biotechnology activities by classification: Other	Total	2.1
% International revenues related to biotechnology activities by classification: Other	Main	1.6
% International revenues related to biotechnology activities by classification: Other	Secondary	5.1
% International revenues related to biotechnology activities by classification: Other	Tool required	1.0